drugset
drugset / Trial / NCT07093255

Safety, PK and PD of FLQ-101 in Premature Neonates

NCT07093255 ↗

Phase 1 Recruiting 18 enrolled FELIQS INC.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.

Timeline

Start
2026-04-03
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject FLQ-101 Unknown — —

Indications

retinopathy of prematurity